Compile Data Set for Download or QSAR
Report error Found 26 Enz. Inhib. hit(s) for PDB: 8FD9
TargetTyrosine-protein kinase BTK(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM50175583(ACP-196 | Acalabrutinib | US9758524, Example 6 | U...)
Affinity DataEC50: <10nMAssay Description:Btk enzyme (His-Btk (Millipore catalog #14-552), is diluted to 0.4 U/mL in KR buffer (10 mM Tris-HCl, 10 mM MgCl2, 0.01% Tween-20, 0.05% NaN3, 1 mM D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent
PDB3D3D Structure (crystal)
TargetTyrosine-protein kinase BTK(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM50175583(ACP-196 | Acalabrutinib | US9758524, Example 6 | U...)
Affinity DataEC50: <10nMAssay Description:Btk enzyme (His-Btk (Millipore catalog #14-552), is diluted to 0.4 U/mL in KR buffer (10 mM Tris-HCl, 10 mM MgCl2, 0.01% Tween-20, 0.05% NaN3, 1 mM D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2019
Entry Details
US Patent
PDB3D3D Structure (crystal)
TargetTyrosine-protein kinase BTK(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM50175583(ACP-196 | Acalabrutinib | US9758524, Example 6 | U...)
Affinity DataEC50: <10nMAssay Description:Btk enzyme activity is measured using the IMAP (immobilized metal ion affinity-based fluorescence polarization) assay as outlined below.Btk enzyme (H...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/12/2021
Entry Details
US Patent
PDB3D3D Structure (crystal)
TargetTyrosine-protein kinase BTK(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM50175583(ACP-196 | Acalabrutinib | US9758524, Example 6 | U...)
Affinity DataEC50:  9.20nMAssay Description:Inhibition of BTK in human whole bloodMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/22/2023
Entry Details
PubMedPDB3D3D Structure (crystal)
TargetTyrosine-protein kinase BTK(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM50175583(ACP-196 | Acalabrutinib | US9758524, Example 6 | U...)
Affinity DataKd:  2.60nMAssay Description:Binding affinity to BTK (unknown origin) assessed as dissociation constant by KINOMEscan analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/22/2023
Entry Details
PubMedPDB3D3D Structure (crystal)
TargetTyrosine-protein kinase BTK(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM50175583(ACP-196 | Acalabrutinib | US9758524, Example 6 | U...)
Affinity DataKd:  21nMAssay Description:Binding affinity to DNA-tagged recombinant BTK (unknown origin) measured after 1 hr by biotinylated-ligand affinity bead-based qPCR analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details Article
PubMedPDB3D3D Structure (crystal)
TargetTyrosine-protein kinase BTK(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM50175583(ACP-196 | Acalabrutinib | US9758524, Example 6 | U...)
Affinity DataIC50: 3nMAssay Description:Irreversible inhibition of BTK (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/21/2024
Entry Details
PubMedPDB3D3D Structure (crystal)
TargetTyrosine-protein kinase BTK(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM50175583(ACP-196 | Acalabrutinib | US9758524, Example 6 | U...)
Affinity DataIC50: 3nMAssay Description:Irreversible inhibition of recombinant human BTKMore data for this Ligand-Target Pair
In Depth
Date in BDB:
4/21/2024
Entry Details
PubMedPDB3D3D Structure (crystal)
TargetTyrosine-protein kinase BTK(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM50175583(ACP-196 | Acalabrutinib | US9758524, Example 6 | U...)
Affinity DataIC50: 3nMAssay Description:Inhibition of BTK (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/19/2023
Entry Details
PubMedPDB3D3D Structure (crystal)
TargetTyrosine-protein kinase BTK(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM50175583(ACP-196 | Acalabrutinib | US9758524, Example 6 | U...)
Affinity DataIC50: 3nMAssay Description:Inhibition of BTK (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2020
Entry Details Article
PubMedPDB3D3D Structure (crystal)
TargetTyrosine-protein kinase BTK(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM50175583(ACP-196 | Acalabrutinib | US9758524, Example 6 | U...)
Affinity DataIC50: 3nMAssay Description:Inhibition of BTK (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details Article
PubMedPDB3D3D Structure (crystal)
TargetTyrosine-protein kinase BTK(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM50175583(ACP-196 | Acalabrutinib | US9758524, Example 6 | U...)
Affinity DataIC50: 3.10nMAssay Description:Inhibition of recombinant BTK (unknown origin) preincubated for 1 hr followed by ATP addition by IMAP assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
9/13/2017
Entry Details Article
PubMedPDB3D3D Structure (crystal)
TargetTyrosine-protein kinase BTK(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM50175583(ACP-196 | Acalabrutinib | US9758524, Example 6 | U...)
Affinity DataIC50: 3.10nMAssay Description:Inhibition of His-tagged recombinant human His-tagged full length BTK expressed in baculovirus expression system using Tyr01 peptide as substrate pre...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/28/2022
Entry Details Article
PubMedPDB3D3D Structure (crystal)
TargetTyrosine-protein kinase BTK(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM50175583(ACP-196 | Acalabrutinib | US9758524, Example 6 | U...)
Affinity DataIC50: 5.10nMAssay Description:Inhibition of BTK (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/22/2023
Entry Details
PubMedPDB3D3D Structure (crystal)
TargetTyrosine-protein kinase BTK(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM50175583(ACP-196 | Acalabrutinib | US9758524, Example 6 | U...)
Affinity DataIC50: 11nMAssay Description:Inhibition of BTK phosphorylation at Tyr 223 residue in human Ramos cell incubated for 3 hrs by HTRF-based analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
4/22/2024
Entry Details
PubMedPDB3D3D Structure (crystal)
TargetTyrosine-protein kinase BTK(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM50175583(ACP-196 | Acalabrutinib | US9758524, Example 6 | U...)
Affinity DataIC50: 18.6nMAssay Description:The substrate solution was prepared by adding the substrate poly(Glu, Tyr) sodium salt (Sigma Aldrich, St. Louis, Mo.) to the substrate reaction buff...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent
PDB3D3D Structure (crystal)
TargetTyrosine-protein kinase BTK(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM50175583(ACP-196 | Acalabrutinib | US9758524, Example 6 | U...)
Affinity DataIC50: 19nMAssay Description:Inhibition of full-length human recombinant BTK using FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2 as substrate measured after 60 mins by caliper assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details Article
PubMedPDB3D3D Structure (crystal)
TargetTyrosine-protein kinase BTK(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM50175583(ACP-196 | Acalabrutinib | US9758524, Example 6 | U...)
Affinity DataIC50: 24nMAssay Description:Inhibition of BTK in vitamin D3 differentiated human THP1 cells assessed as inhibition of FCgammaR-induced IL8 production measured after 24 hrs by HT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details Article
PubMedPDB3D3D Structure (crystal)
TargetTyrosine-protein kinase BTK(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM50175583(ACP-196 | Acalabrutinib | US9758524, Example 6 | U...)
Affinity DataIC50: 24nMAssay Description:Inhibition of full-length N-terminal GST tagged BTK (2 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2022
Entry Details Article
PubMedPDB3D3D Structure (crystal)
TargetTyrosine-protein kinase BTK(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM50175583(ACP-196 | Acalabrutinib | US9758524, Example 6 | U...)
Affinity DataIC50: 47nMAssay Description:1: Test Principle:Mobility-Shift Assay, which is microfluidic chip technology, applies the basic concept of capillary electrophoresis to microfluidic...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/14/2021
Entry Details
US Patent
PDB3D3D Structure (crystal)
TargetTyrosine-protein kinase BTK(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM50175583(ACP-196 | Acalabrutinib | US9758524, Example 6 | U...)
Affinity DataIC50: 100nMAssay Description:Activity of BTK protein kinase was tested by Caliper mobility shift assay (referring to J Biomol Screen 14:31, 2009). The compound of the present dis...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/2/2021
Entry Details
US Patent
PDB3D3D Structure (crystal)
TargetTyrosine-protein kinase BTK(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM50175583(ACP-196 | Acalabrutinib | US9758524, Example 6 | U...)
Affinity DataIC50: 198nMAssay Description:Inhibition of BTK in human whole blood-derived CD19+ B cells assessed as suppression of anti-IgM stimulated-CD69 expression preincubated for 1 hr fol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2019
Entry Details Article
PubMedPDB3D3D Structure (crystal)
TargetTyrosine-protein kinase BTK(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM50175583(ACP-196 | Acalabrutinib | US9758524, Example 6 | U...)
Affinity DataIC50: 203nMAssay Description:Inhibition of BTK in human B cells assessed as reduction in anti-IgM/IL4-stimulated CD69 expression on B cells preincubated for 60 mins followed by a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details Article
PubMedPDB3D3D Structure (crystal)
TargetTyrosine-protein kinase BTK(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM50175583(ACP-196 | Acalabrutinib | US9758524, Example 6 | U...)
Affinity DataIC50: 297nMAssay Description:Inhibition of BTK in human whole blood derived-basophils assessed as suppression of IgE mediated-FcepsilonR ligation-stimulated CD63 expressionMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2019
Entry Details Article
PubMedPDB3D3D Structure (crystal)
TargetTyrosine-protein kinase BTK(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM50175583(ACP-196 | Acalabrutinib | US9758524, Example 6 | U...)
Affinity DataIC50: 747nMAssay Description:Inhibition of BTK in human basophils assessed as reduction in anti-IgE mouse IgG1 antibody Le2-stimulated CD63 expression on basophil preincubated fo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details Article
PubMedPDB3D3D Structure (crystal)
TargetTyrosine-protein kinase BTK [C481S](Human)
TRANSTHERA SCIENCES (NANJING), INC.

US Patent
LigandPNGBDBM50175583(ACP-196 | Acalabrutinib | US9758524, Example 6 | U...)
Affinity DataIC50: 815nMAssay Description:The substrate solution was prepared by adding the substrate poly(Glu, Tyr) sodium salt (Sigma Aldrich, St. Louis, Mo.) to the substrate reaction buff...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2022
Entry Details
US Patent
PDB3D3D Structure (crystal)